Can-Fite BioPharma Ltd. (NYSE: CANF) reported a net loss of $4.60 million for the six months ended June 30, 2026, compared to a loss of $4.87 million in the same period last year. The biotechnology firm also announced that blinded overall survival data in its pivotal Phase III liver cancer study appears longer than anticipated.

The company generated revenues of $0.20 million, unchanged from H1 2025, derived from advance payments under existing out-licensing agreements. Research and development expenses rose 13.86% to $3.45 million, driven by acceleration in its Namodenoson and Piclidenoson programs. General and administrative expenses fell 31.40% to $1.42 million, primarily due to lower investor relations costs.

Clinical Progress

Can-Fite provided updates on three key therapeutic areas:

• Hepatocellular Carcinoma: Blinded overall survival in the ongoing pivotal Phase III study of Namodenoson appears longer than originally anticipated. The company is evaluating an earlier timing for the planned interim analysis.
• Pancreatic Cancer: A Phase 2a study of Namodenoson achieved its primary safety endpoint and demonstrated durable overall survival outcomes in heavily pretreated patients. An abstract has been accepted for presentation at the ESMO Congress 2026.
• Psoriasis: Enrolment of the first 247 patients in the pivotal Phase 3 study of Piclidenoson is complete. The study has reached the pre-specified interim analysis stage, with results expected in Q1 2027.

Financial Performance

Net financial income increased to $0.08 million from $0.02 million in the prior year, mainly due to higher interest income from bank deposits. Cash and cash equivalents stood at $7.03 million as of June 30, 2026, down from $8.53 million at year-end 2025. The decrease was primarily due to operating losses, partially offset by proceeds from share and warrant issuances.

What the Numbers Show

The narrowing of the net loss was driven entirely by operational cost control rather than revenue growth or R&D efficiency. While R&D spending accelerated by $0.42 million to support late-stage trials, G&A expenses contracted by $0.65 million. This divergence indicates that the improvement in the bottom line resulted from reduced administrative overhead, specifically investor relations costs, rather than a reduction in clinical development burn rate.

Can-Fite BioPharma Ltd (NYSE: CANF) secured $4 million in gross proceeds through a warrant exercise agreement while reporting extended survival trends in its pivotal Phase 3 liver cancer study.

The clinical-stage biotechnology firm observed longer-than-expected blinded overall survival in its ongoing trial evaluating Namodenoson for advanced hepatocellular carcinoma (HCC). The study focuses on HCC patients with Child-Pugh B7 cirrhosis, utilizing overall survival as its primary efficacy endpoint.

Phase 3 Liver Cancer Trial Progress

Because the observed data reflect a pooled, blinded population across both treatment arms, the company cannot draw conclusions regarding drug efficacy or comparative differences yet. However, due to the prolonged survival rates, management is assessing an earlier timeline for the trial’s planned interim analysis.

Warrant Exercise Details

In a concurrent financial update, the firm secured an immediate warrant exercise agreement for up to 1,591,738 American Depositary Shares (ADSs). Originally issued in March 2026 with a $5 exercise price, the company reduced the exercise price to $2.50 per ADS to encourage immediate cash execution.

To incentivize the transaction, the business will issue new unregistered warrants allowing holders to purchase up to 3,183,476 additional ADSs at $2.50 per share. The initial exercise generates roughly $4 million in gross proceeds prior to deducting placement agent fees.

Management plans to allocate the net capital toward research and development, clinical trials, working capital and general corporate activities.

What the Numbers Show

The warrant structure reveals a significant dilution potential relative to immediate capital raised. For every one ADS exercised at the reduced price of $2.50, the company is issuing rights to purchase two additional ADSs at the same price. This 1:2 ratio between exercised shares and new warrants issued suggests a strategy prioritizing immediate liquidity for clinical operations over long-term share count preservation.

Can Fite Biopharma shares were down 22.49% at $2.55 at the time of publication Wednesday.